A human blood–retina barrier-on-a-chip
Ranking
Observed public metrics from 1 member.
Merged summary
TL;DR - A Nature Methods paper (published 06 August 2026) reporting a microfluidic "organ-on-a-chip" that reconstitutes the human blood–retina barrier in vitro, offering a human-relevant platform for studying ocular barrier biology and drug permeability. Note: only the title and citation metadata were provided, so the details below are inferred from the title and venue, not from reported results.
- Subject is a microphysiological/organ-on-a-chip system modeling the blood–retina barrier — the selective interface (retinal endothelium plus supporting retinal cell types) that regulates molecular exchange into the retina.
- Published in Nature Methods (doi:10.1038/s41592-026-03191-x), indicating the contribution is primarily a new experimental method/platform rather than a computational or AI model.
- Typical utility of such platforms: human-cell-based alternative to animal models for testing barrier integrity, drug delivery to the eye, and disease mechanisms such as diabetic retinopathy or age-related macular degeneration.
- No quantitative results, cell sources, device design, or validation data are available in the supplied content; the full text would be needed to assess performance claims.
Sources (1)
A human blood–retina barrier-on-a-chip
TL;DR - A Nature Methods paper (published 06 August 2026) reporting a microfluidic "organ-on-a-chip" that reconstitutes the human blood–retina barrier in vitro, offering a human-relevant platform for studying ocular barrier biology and drug permeability. Note: only the title and citation metadata were provided, so the details below are inferred from the title and venue, not from reported results.
- Subject is a microphysiological/organ-on-a-chip system modeling the blood–retina barrier — the selective interface (retinal endothelium plus supporting retinal cell types) that regulates molecular exchange into the retina.
- Published in Nature Methods (doi:10.1038/s41592-026-03191-x), indicating the contribution is primarily a new experimental method/platform rather than a computational or AI model.
- Typical utility of such platforms: human-cell-based alternative to animal models for testing barrier integrity, drug delivery to the eye, and disease mechanisms such as diabetic retinopathy or age-related macular degeneration.
- No quantitative results, cell sources, device design, or validation data are available in the supplied content; the full text would be needed to assess performance claims.